Terapia de mantenimiento con inhibidores de PARP en cáncer de ovario: Un nuevo concepto para aumentar la supervivencia en la enfermedad recurrente

17 / 40

Treatment
PFS
Median
(95% CI)
(Months)
Hazard Ratio
(95% CI)
p-value
Niraparib
(N=234)
9.3
(7.2, 11.2) 0.45
(0.338, 0.607)
p<0.0001
Placebo
(N=116)
3.9
(3.7, 5.5)
PFS: non-gBRCAmut PFS: HRD positive
Treatment
PFS
Median
(95% CI)
(months)
Hazard Ratio
(95% CI)
P value
Niraparib
(N=106)
12.9
(8.1, 15.9)
0.38
(0.243,
0.586)
P<0.0001
Placebo
(N=56)
3.8
(3.5, 5.7)
Treatment
PFS
Median
(95% CI)
(Months)
Hazard Ratio
(95% CI)
p-value
Niraparib
(N=92)
6.9
(5.6, 9.6)
0.58
(0.361,
0.922)
p=0.0226
Placebo
(N=42)
3.8
(3.7, 5.6)
PFS: HRD negative
Mirza et al. N Eng J Med 2016
Maintenance with Niraparib in gBRCAwt
NOVA: PFS by biomarker cohorts